Abstract
Background The relentless advance of the SARS-CoV-2 virus pandemic has resulted in a significant burden on countries, regardless of their socio-economic conditions. The virus has infected more than 2.5 million people worldwide, causing to date more than 150,000 deaths in over 210 countries.
Objective The aim of this study was to describe the trends in cases, tests and deaths related to novel coronavirus disease (COVID-19) in Latin American and Caribbean (LAC) countries.
Methodology Data were retrieved from the WHO-Coronavirus Disease (COVID-2019) situation reports and the Center for Systems Science and Engineering (CSSE) databases from Johns Hopkins University. Descriptive statistics including death rates, cumulative mortality and incidence rates, as well as testing rates per population at risk were performed. A comparison analysis among countries with ≥50 confirmed cases was performed from February 26th, 2020 to April 8th, 2020.
Results Brazil had the greatest number of cases and deaths in the region. Panama experienced a rapid increase in the number of confirmed cases with Trinidad and Tobago, Bolivia and Honduras having the highest case fatality rates. Panama and Chile conducted more tests per million inhabitants and more tests per day per million inhabitants, followed by Uruguay and El Salvador. Dominican Republic, Bolivia, Ecuador and Brazil had the highest positive test rates.
Conclusions The COVID-19 disease pandemic caused by the SARS-CoV-2 virus has progressed rapidly in LAC countries. Some countries have been affected more severely than others, with some adopting similar disease control methods to help slow down the spread of the virus. With limited testing and other resources, social distancing is needed to help alleviate the strain on already stretched health systems.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We thank Universidad de las Americas for its economic support funding the publication of this document through the approved project entitled "Clinical, genetic and epidemiological characterization of COVID-19 and SARS-CoV-2 in Ecuador".
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data is publicly available through the servers that were described within the methodology section.
Abbreviations
- CCC
- Cumulative Confirmed Cases
- CCD
- Cumulative Confirmed Deaths
- CICC
- Cumulative Incidence of Confirmed Cases
- CICD
- Cumulative Incidence of Confirmed Deaths
- CFR%
- Case Fatality Rate
- COVID-19
- Novel Coronavirus Disease
- CSSE
- Center for Systems Science and Engineering
- DCMI
- Daily Cases per Million Inhabitants
- DTMI
- Daily Tests per Million Inhabitants
- GISAID
- Global Initiative on Sharing All Influenza Data
- LAC
- Latin America and Caribbean
- MERS
- Middle-East Respiratory Syndrome
- SARS
- Severe Acute Respiratory Syndrome
- TMI
- Tests per Million Inhabitants
- PTR%
- Positive Test Rate
